NASDAQ:KLDO - Kaleido Biosciences Stock Price, Forecast & News

Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."

Kaleido Biosciences Inc (NASDAQ:KLDO) announced its quarterly earnings data on Wednesday, October, 30th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.15. View Kaleido Biosciences' Earnings History.

Kaleido Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, February 19th 2020. View Earnings Estimates for Kaleido Biosciences.

5 brokers have issued 1 year price objectives for Kaleido Biosciences' shares. Their forecasts range from $15.00 to $20.00. On average, they anticipate Kaleido Biosciences' stock price to reach $17.70 in the next year. This suggests a possible upside of 165.0% from the stock's current price. View Analyst Price Targets for Kaleido Biosciences.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kaleido Biosciences.

Media coverage about KLDO stock has trended very negative on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kaleido Biosciences earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Kaleido Biosciences.

Kaleido Biosciences saw a increase in short interest in January. As of January 15th, there was short interest totalling 1,820,000 shares, an increase of 20.5% from the December 31st total of 1,510,000 shares. Based on an average daily volume of 126,200 shares, the short-interest ratio is currently 14.4 days. Approximately 20.2% of the company's stock are sold short. View Kaleido Biosciences' Current Options Chain.

Some companies that are related to Kaleido Biosciences include ANI Pharmaceuticals (ANIP), Quanterix (QTRX), Integral Diagnostics (IDX), Rhythm Pharmaceuticals (RYTM), Cerus (CERS), Collegium Pharmaceutical (COLL), Extendicare (EXE), Atara Biotherapeutics (ATRA), CannTrust (CNTTF), Paradigm Biopharmaceuticals (PAR), Avrobio (AVRO), Frequency Therapeutics (FREQ), Cellectis (CLLS), DiaMedica Therapeutics (DMCAF) and Provention Bio (PRVB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Precision BioSciences (DTIL), Gossamer Bio (GOSS), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Exxon Mobil (XOM), QUALCOMM (QCOM), Pfizer (PFE) and Akero Therapeutics (AKRO).

(KLDO) raised $101 million in an IPO on Thursday, February 28th 2019. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Kaleido Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (6.94%), Victory Capital Management Inc. (0.43%), Victory Capital Management Inc. (0.43%), State Street Corp (0.40%), Goldman Sachs Group Inc. (0.37%) and Bank of America Corp DE (0.20%). Company insiders that own Kaleido Biosciences stock include Michael W Bonney and Ventures Fund V LP Flagship. View Institutional Ownership Trends for Kaleido Biosciences.

KLDO stock was sold by a variety of institutional investors in the last quarter, including Bainco International Investors, Victory Capital Management Inc. and Victory Capital Management Inc.. View Insider Buying and Selling for Kaleido Biosciences.

KLDO stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Goldman Sachs Group Inc., Bank of America Corp DE, Jacobs Levy Equity Management Inc., State Street Corp, Oxford Asset Management LLP, Bank of New York Mellon Corp and Charles Schwab Investment Management Inc.. Company insiders that have bought Kaleido Biosciences stock in the last two years include Michael W Bonney and Ventures Fund V LP Flagship. View Insider Buying and Selling for Kaleido Biosciences.

Shares of KLDO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KLDO stock can currently be purchased for approximately $6.68.

Kaleido Biosciences has a market capitalization of $200.80 million. Kaleido Biosciences employs 118 workers across the globe.View Additional Information About Kaleido Biosciences.